Genetic Technologies Ltd stock is up 5.8% since 30 days ago. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 42.11% of the previous 18 November’s closed higher than October.
Genetic Technologies Limited provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. Its lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. The company also develops other risk assessment tests across a range of diseases, which include cardiovascular, type 2 diabetes, prostate cancer, and melanoma.